PALO ALTO, Calif., April 9 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK) announced that updated clinical data from its multicenter
Phase 2 trial of the triplet combination of TELCYTA(R) (canfosfamide HCl,
TLK286), carboplatin and paclitaxel will be presented at the 98th annual
meeting of the American Association for Cancer Research (AACR) in Los
Angeles. Preclinical studies of cellular and molecular correlates of
synergistic cancer cell growth inhibition with TELCYTA in combination with
standard chemotherapy, and studies describing TELCYTA's potential
anti-angiogenic activity, also will be presented.
Details of the presentations are as follows:
-- Phase 2 Multicenter Dose-Ranging Trial of TLK286 (Canfosfamide HCl) in
Combination with Carboplatin and Paclitaxel as First-Line Treatment for
Advanced Non-Small Cell Lung Cancer; Tuesday, April 17, 2007,
8:00 am - noon; Phase II-III Adult Clinical Trials; Abstract # 3521
-- Cellular and Molecular Correlates of Synergistic Growth Inhibition in
Human Lung Cancer Cells by TLK286 (Canfosfamide HCl), a Novel
Glutathione Analog Prodrug, in Combination with Paclitaxel and
Carboplatin; Sunday, April 15, 2007, 8:00 am - noon; Drug Delivery I;
Abstract # 1502
-- TLK286 (Canfosfamide HCl), a Novel Glutathione Analog Prodrug, Exhibits
Antiangiogenic Effects Including the Inhibition of Human Endothelial
Cell Proliferation and Capillary Tubule Formation In Vitro; Tuesday,
April 17, 2007, 1:00 - 5:00 pm; Angiogenesis II: Novel Inhibitors;
Abstract # 4622
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on
discovering, developing and commercializing novel small molecule drugs to
treat serious diseases. The company's most advanced drug development
candidate is TELCYTA, a tumor-activated small molecule product candidate in
clinical development for the treatment of advanced ovarian cancer and
non-small cell lung cancer. A second drug development candidate,
TELINTRA(TM) (TLK199), is in clinical development in myelodysplastic
syndrome. Telik's product candidates were discovered using its proprietary
drug discovery technology, TRAP(TM), which enables the rapid and efficient
discovery of small molecule drug candidates. Additional information is
available at http://www.telik.com.
This press release contains "forward-looking" statements, including
statements regarding the potential for TELCYTA to treat one or more types
of cancer. There are important factors that could cause Telik's results to
differ materially from those indicated by these forward-looking statements,
including, among others, that none of Telik's product candidates have been
determined to be safe or effective in humans or been approved for
marketing, clinical trials of Telik's product candidates may take several
years to complete and may not be successful, success in preclinical testing
and early clinical trials does not ensure that later clinical trials will
be successful and interim results of clinical trials do not necessarily
predict final results. Detailed information regarding factors that may
cause actual results to differ materially from the results expressed or
implied by statements in this press release may be found in Telik's
periodic filings with the Securities and Exchange Commission, including the
factors described in the section entitled "Risk Factors" in its annual
report on Form 10-K for the year ended December 31, 2006. Telik does not
undertake any obligation to update forward-looking statements contained in
this press release.
NOTE: TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks
or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.
 back to top
Related links:
http://www.telik.com/
CONTACT:
Carol D. DeGuzman, Senior Director, Corporate
Communications of Telik, +1-650-845-7728, or cdeguzman@telik.com
|
